April 22 (Reuters) - The U.S. FDA approved ImmunityBio's combination therapy to treat a type of bladder cancer, the regulator said on Monday, which would help bring the company's first product to market. (Reporting by Puyaan Singh and Pratik Jain in Bengaluru; Editing by Shailesh Kuber)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.005 USD | -1.56% | -2.42% | +20.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.52% | 4.22B | |
+18.78% | 125B | |
+13.88% | 108B | |
-7.35% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-14.06% | 16.37B | |
+1.83% | 13.58B | |
+27.69% | 11.66B |
- Stock Market
- Equities
- IBRX Stock
- News ImmunityBio, Inc.
- U.S. FDA approves ImmunityBio's bladder cancer therapy